GCM
LXRX icon

Graham Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Graham Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.5K Sell
23,541
-10,486
-31% -$20.4K ﹤0.01% 1198
2026
Q1 		$53.1K Sell
34,027
-75,873
-69% -$110K ﹤0.01% 1089
2025
Q4 		$126K Buy
+109,900
New +$151K ﹤0.01% 1123

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Graham Capital Management's LXRX Position: Q2 2026 in Review

Graham Capital Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 31% in Q2 2026, selling an estimated $20.4K and leaving 23,541 shares worth $56.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1198.

Graham Capital Management first reported a position in LXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $126K in Q4 2025. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Graham Capital Management held 23,541 shares of Lexicon Pharmaceuticals worth $56.5K as of Q2 2026.
  • Graham Capital Management sold 10,486 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $20.4K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1198 holding.
  • Graham Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Graham Capital Management's Lexicon Pharmaceuticals position peaked at $126K in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.